title: Control of malignant ascites with spironolactone.
abstract: Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment. Plasma renin activity was raised in all of 5 patients in whom it was measured, whereas aldosterone was raised in only 3; these results are similar to those found in ascites due to cirrhosis.
mesh_terms: D000008:Abdominal Neoplasms / Q000150:complications* / Q000378:metabolism; D000450:Aldosterone / Q000097:blood; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D001943:Breast Neoplasms / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013148:Spironolactone; D000450:Aldosterone; D012964:Sodium; D012083:Renin